Scholarlink

The approved nicotinamide adenine dinucleotide (NAD+) pharmaceutical preparation for marketing is coenzyme I for injection, marketed by Kaifeng Kangnuo Pharmaceutical Co in1983. This lyophilized powder injection primarily contains NAD+, a crucial coenzyme for cellular functions, involved in redox reactions and macromolecular modifications. Research indicates that NAD+ is pivotal in aging and its related diseases, which can be mitigated or reversed by restoring NAD+ levels. Administration of coenzyme I by injection effectively addresses NAD+ deficiency, relieves aging-related diseases, and has the potential to enhance human health and longevity.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Coenzyme I Drug

  • 章节

  • 发表日期：

    2025年

查看全文
  • Qian Jiang,
  • Li Luo,
  • Zhi Jiang,
  • Yuanyuan Qin,
  • Lei Wang,
  • Kanglin Wang,
  • Wei Wang

摘要

The approved nicotinamide adenine dinucleotide (NAD+) pharmaceutical preparation for marketing is coenzyme I for injection, marketed by Kaifeng Kangnuo Pharmaceutical Co in1983. This lyophilized powder injection primarily contains NAD+, a crucial coenzyme for cellular functions, involved in redox reactions and macromolecular modifications. Research indicates that NAD+ is pivotal in aging and its related diseases, which can be mitigated or reversed by restoring NAD+ levels. Administration of coenzyme I by injection effectively addresses NAD+ deficiency, relieves aging-related diseases, and has the potential to enhance human health and longevity.